OraSure Technologies (OSUR) Q4 2024 earnings summary

Executive summary

• Q4 2024 core revenue grew 10% year-over-year, driven by diagnostics and sample management, while total revenue aligned with guidance despite a sharp decline in COVID-19 sales.

• Strategic transformation advanced with the acquisition of Sherlock Biosciences, expanding the molecular diagnostics pipeline.

• FDA approved expanded labeling for the OraQuick HIV self-test to include adolescents 14+, increasing market access.

• Awarded a $7.5M contract (potentially $11M) for Marburg virus rapid antigen test development.

• Positive operating cash flow from core business in Q4, with a strong balance sheet and zero debt.

Financial highlights

• Q4 total revenue: $37.4M; core revenue: $36.5M (+10% YoY); diagnostics: $18.8M (+9% YoY); sample management: $14.8M (+14% YoY).

• COVID-19 products contributed $1M; risk assessment testing contributed $2.1M.

• GAAP gross margin: 36.2% (includes $1M inventory reserve); non-GAAP gross margin: 40.1%.

• GAAP operating loss: $12.4M; non-GAAP operating loss: $6.7M.

• Cash and equivalents: $268M at quarter end.

Outlook and guidance

• Q1 2025 total revenue guidance: $27.5M–$31.5M; core revenue: $27M–$31M (includes $1M risk assessment testing).

• COVID-19 product revenue expected at $0.5M in Q1.

• Gross margin expected in low 40s for Q1, expanding toward 50% for full year 2025.

• Q1 core operating expenses expected in low $20M range, plus $10M innovation spend ($7–8M for Sherlock).